BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29674052)

  • 1. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.
    Azevedo R; Soares J; Gaiteiro C; Peixoto A; Lima L; Ferreira D; Relvas-Santos M; Fernandes E; Tavares A; Cotton S; Daniel-da-Silva AL; Santos LL; Vitorino R; Amado F; Ferreira JA
    Talanta; 2018 Jul; 184():347-355. PubMed ID: 29674052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and optimization of lectin functionalized nanoprobes for the selective recovery of glycoproteins from human body fluids.
    Ferreira JA; Daniel-da-Silva AL; Alves RM; Duarte D; Vieira I; Santos LL; Vitorino R; Amado F
    Anal Chem; 2011 Sep; 83(18):7035-43. PubMed ID: 21809823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
    Cotton S; Azevedo R; Gaiteiro C; Ferreira D; Lima L; Peixoto A; Fernandes E; Neves M; Neves D; Amaro T; Cruz R; Tavares A; Rangel M; Silva AMN; Santos LL; Ferreira JA
    Mol Oncol; 2017 Aug; 11(8):895-912. PubMed ID: 28156048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico approaches for unveiling novel glycobiomarkers in cancer.
    Azevedo R; Silva AMN; Reis CA; Santos LL; Ferreira JA
    J Proteomics; 2018 Jan; 171():95-106. PubMed ID: 28782717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBC
    Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
    Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
    Peixoto A; Ferreira D; Azevedo R; Freitas R; Fernandes E; Relvas-Santos M; Gaiteiro C; Soares J; Cotton S; Teixeira B; Paulo P; Lima L; Palmeira C; Martins G; Oliveira MJ; Silva AMN; Santos LL; Ferreira JA
    J Exp Clin Cancer Res; 2021 Jun; 40(1):191. PubMed ID: 34108014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling.
    Kreunin P; Zhao J; Rosser C; Urquidi V; Lubman DM; Goodison S
    J Proteome Res; 2007 Jul; 6(7):2631-9. PubMed ID: 17518487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
    Llop E; Peracaula R
    Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoproteomic Alterations in Drug-Resistant Nonsmall Cell Lung Cancer Cells Revealed by Lectin Magnetic Nanoprobe-Based Mass Spectrometry.
    Waniwan JT; Chen YJ; Capangpangan R; Weng SH; Chen YJ
    J Proteome Res; 2018 Nov; 17(11):3761-3773. PubMed ID: 30261726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
    Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
    Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer.
    Lindén M; Lind SB; Mayrhofer C; Segersten U; Wester K; Lyutvinskiy Y; Zubarev R; Malmström PU; Pettersson U
    Proteomics; 2012 Jan; 12(1):135-44. PubMed ID: 22065568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.
    Yang N; Feng S; Shedden K; Xie X; Liu Y; Rosser CJ; Lubman DM; Goodison S
    Clin Cancer Res; 2011 May; 17(10):3349-59. PubMed ID: 21459797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
    Zoidakis J; Makridakis M; Zerefos PG; Bitsika V; Esteban S; Frantzi M; Stravodimos K; Anagnou NP; Roubelakis MG; Sanchez-Carbayo M; Vlahou A
    Mol Cell Proteomics; 2012 Apr; 11(4):M111.009449. PubMed ID: 22159600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural alterations of sugar chains in urine fibronectin from bladder cancer patients and its enzymatic mechanism.
    Guo JM; Zhang XY; Chen HL; Wang GM; Zhang YK
    J Cancer Res Clin Oncol; 2001 Aug; 127(8):512-9. PubMed ID: 11501752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
    Glybochko PV; Alyaev JG; Potoldykova NV; Polyakovsky KA; Vinarov AZ; Glukhov AI; Gordeev SA
    Urologiia; 2016 Aug; (4):76-81. PubMed ID: 28247730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression.
    Andreu Z; Otta Oshiro R; Redruello A; López-Martín S; Gutiérrez-Vázquez C; Morato E; Marina AI; Olivier Gómez C; Yáñez-Mó M
    Eur J Pharm Sci; 2017 Feb; 98():70-79. PubMed ID: 27751843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.